GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Paper] amylin co-agonism is genuinely different pharmacology, not just more GLP-1 — 53 comments in the full submission. View in context.
1.2k
c/glp1science·submitted 18 days ago by u/aleksi_eriksen

[Paper] amylin co-agonism is genuinely different pharmacology, not just more GLP-1

Paperbranch of 7 comments

Long-ish post, sorry. tl;dr at the bottom. I have been tracking incretin against triglycerides for 13 weeks because I could not find anyone who had. The correlation is weaker than I expected, which is itself mildly interesting given how confidently people link the two in here. Caveats up front: one person, one lab,…

Read the full submission and all 53 comments →

This branch

7 comments, started 17 days ago
u/yusuf_ramos76 points·17 days ago·edited

I am going to push back on this slightly.

replysharereportpermalink
u/nadia_bakker61 points·17 days ago

This is the "correlation is mechanism" thing again. You changed three variables at once.

replysharereportpermalink
u/cato_batista50 points·17 days ago·edited

Disagree but this is the good kind of wrong — it is specific enough to be checked.

replysharereportpermalink
u/ferran_dahlberg35 points·16 days ago

This is correct. Rodent data is investigational, not predictive.

replysharereportpermalink
u/fatima_kowalski51 points·17 days ago

incretin physiology is mechanism, the mechanism layer

replysharereportpermalink
u/wholesome_lurker0 points·16 days ago

the 2-day half-life means week 2 is still ramp-up pharmacokinetically

replysharereportpermalink
u/aleksi_eriksenOP1 point·16 days ago

The half-life is 7 hours, which means week 7 is genuinely still ramp-up. Week 38 is steady state.

replysharereportpermalink

← back to the whole thread

About c/glp1science

The mechanism layer: incretin physiology, receptor distribution, gastric emptying, central appetite signalling, glucagon-receptor contribution, amylin co-agonism, and the pharmacokinetics that make weekly dosing possible. Papers get cited by journal and year or they get a [needs source] reply.

50kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/glp1science
c/glp1science rules
  1. Cite the paper: journal, year, first author. Links optional, citation mandatory.
  2. Mechanistic speculation is welcome if flaired as speculation.
  3. No extrapolating rodent data to human dosing without saying that is what you are doing.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/trialwatch_theou/gastric_emptying_gu/sig_figs_sam
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →